Chief Executive Officer, GPN Vaccines
| Role | Organisation | Sources |
|---|---|---|
| Chief Executive Officer | GPN Vaccines | gpnvaccines.com, Brandon BioCatalyst, Brandon Capital, Techboard |
Stories naming Professor Tim Hirst. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
GPN Vaccines, an Adelaide biotech, has closed a A$18 million Series B1 that beat its 15 million target, co-led by Forepont Capital and Mike Gregg, with Kern Capital joining as a new investor.
CUREator, Brandon BioCatalyst's government-backed grant program, has awarded $7.21 million across eight Australian biotech firms in its newest round, split between clinical-stage and preclinical recipients.
Also Brandon BioCatalyst portfolio·Startup Daily·ausceleratesa.org
Techboard announces the 2022 Australian Angel Awards winners, honouring Tim Hirst as Angel of the Year and Brisbane Angels for its Clipchamp exit, while recalling past raises and exits including Clarity Pharmaceuticals and Instaclustr.